Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a pioneer in Obstructive Sleep Apnea (OSA) treatment through neuromodulation, has announced its participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference scheduled for March 17-20, 2025.
CEO Olivier Taelman will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. The presentation will be accessible via webcast in the Events section of Nyxoah's Investor Relations website. The company will also be available for one-on-one meetings with institutional investors during the conference.
Nyxoah (Euronext Bruxelles/Nasdaq: NYXH), un pioniere nel trattamento dell'Apnea Ostruttiva del Sonno (OSA) attraverso la neuromodulazione, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale Oppenheimer sui MedTech e Servizi Sanitari programmata per il 17-20 marzo 2025.
Il CEO Olivier Taelman presenterà un intervento aziendale lunedì 17 marzo 2025, alle 8:40 ET. La presentazione sarà accessibile tramite webcast nella sezione Eventi del sito web delle Relazioni con gli Investitori di Nyxoah. L'azienda sarà inoltre disponibile per incontri individuali con investitori istituzionali durante la conferenza.
Nyxoah (Euronext Bruselas/Nasdaq: NYXH), un pionero en el tratamiento de la Apnea Obstructiva del Sueño (OSA) a través de la neuromodulación, ha anunciado su participación en la 35ª Conferencia Anual Oppenheimer sobre MedTech y Servicios de Salud programada para el 17-20 de marzo de 2025.
El CEO Olivier Taelman ofrecerá una presentación corporativa el lunes 17 de marzo de 2025, a las 8:40 a.m. ET. La presentación será accesible a través de un webcast en la sección de Eventos del sitio web de Relaciones con Inversores de Nyxoah. La empresa también estará disponible para reuniones individuales con inversores institucionales durante la conferencia.
Nyxoah (유로넥스트 브뤼셀/나스닥: NYXH)는 신경조절을 통한 폐쇄성 수면 무호흡증 (OSA) 치료의 선구자로서, 2025년 3월 17일부터 20일까지 예정된 오펜하이머 제35회 연례 헬스케어 MedTech 및 서비스 회의에 참여한다고 발표했습니다.
CEO 올리비에 타엘만은 2025년 3월 17일 월요일, 오전 8:40 ET에 기업 발표를 진행할 예정입니다. 발표는 Nyxoah의 투자자 관계 웹사이트의 이벤트 섹션을 통해 웹캐스트로 접근할 수 있습니다. 회사는 또한 회의 동안 기관 투자자들과의 일대일 미팅을 위해 자리할 것입니다.
Nyxoah (Euronext Bruxelles/Nasdaq: NYXH), un pionnier dans le traitement de l'
Le PDG Olivier Taelman présentera une intervention d'entreprise le lundi 17 mars 2025, à 8h40 ET. La présentation sera accessible par webcast dans la section Événements du site Web des Relations Investisseurs de Nyxoah. L'entreprise sera également disponible pour des réunions individuelles avec des investisseurs institutionnels pendant la conférence.
Nyxoah (Euronext Brüssel/Nasdaq: NYXH), ein Pionier in der Behandlung von obstruktiver Schlafapnoe (OSA) durch Neuromodulation, hat seine Teilnahme an der 35. jährlichen Oppenheimer-Konferenz für MedTech und Gesundheitsdienstleistungen, die vom 17. bis 20. März 2025 stattfindet, angekündigt.
CEO Olivier Taelman wird am Montag, den 17. März 2025, um 8:40 Uhr ET eine Unternehmenspräsentation halten. Die Präsentation wird über einen Webcast im Bereich Veranstaltungen der Investor-Relations-Website von Nyxoah zugänglich sein. Das Unternehmen wird während der Konferenz auch für persönliche Gespräche mit institutionellen Investoren zur Verfügung stehen.
- None.
- None.
Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Mont-Saint-Guibert, Belgium – March 3, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which takes place March 17 – 20, 2025.
Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1x1 meetings with institutional investors.
Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s
Investor Relations page.
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Attachment
FAQ
When is Nyxoah (NYXH) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Nyxoah's (NYXH) Oppenheimer conference presentation?
What is Nyxoah's (NYXH) main focus in medical technology?
Will Nyxoah (NYXH) be available for individual investor meetings at the Oppenheimer conference?
Where can investors find Nyxoah's (NYXH) corporate presentation materials?
